Replies to post #202484 on Biotech Values

[CHM_760]

Fair enough.

Here's a recent presentation slide deck if you're interested.
http://ir.ziopharm.com/secfiling.cfm?filingid=1193125-16-617632&CIK=1107421

Here is their June 27th press release:

https://globenewswire.com/news-release/2016/06/27/851655/0/en/ZIOPHARM-Completes-Enrollment-in-Second-Patient-Cohort-and-Initiates-Enrollment-in-Third-Cohort-in-Phase-1-Study-of-Gene-Therapy-Candidate-Ad-RTS-hIL-12-in-Brain-Cancer.html

snip>
The primary objective of the study is to determine the safety and tolerability of a single intratumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. Secondary objectives are to determine the maximum tolerated dose, the immune responses elicited, and assessment of biologic response. The first cohort of seven patients received 20 mg doses of veledimex, the second cohort of six patients received 40 mg doses of veledimex, and the third cohort will receive 30 mg doses of veledimex to refine the effect of activating the immune response within the tumor. The resultant immunologic activity that follows IL-12 expression in the brain suggests that no further dose escalation will be necessary and the optimal dosing may be reached sooner than initially anticipated.

Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at ZIOPHARM, commented: “With the RheoSwitch® (RTS®) technology, the only switch currently in the clinic that operates on gene transcription, we have demonstrated the ability for veledimex to cross the human blood brain barrier and activate production of IL-12 in GBM tumors in a dose-dependent manner, giving us the potential to precisely tune the balance between activity and tolerability.”